|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo single-cell analysis revealed a time-dependent evolution from normal luminal MECs to luminal progenitor-like tumor cells with basal/mesenchymal transdifferentiation during murine BRCA1 BLBC development.
|
31251913 |
2019 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we interbred mice expressing the CRE-recombinase with mice harboring loxP sites at TP53 and BRCA1 (K14-Cre; p53<sup>f/f</sup> Brca1<sup>f/f</sup>) to test the hypothesis that tissue-specific deletion of TP53 and BRCA1 would give rise to tumors reflective of human basal-like breast cancer.
|
30484104 |
2019 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1-associated basal-like breast cancer originates from luminal progenitor cells.
|
30982901 |
2019 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
|
30323900 |
2018 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, metformin treatment elicits a synergistic decline in the breast cancer-initiating cell population and its self-renewal capacity in BRCA1-mutated basal-like breast cancer cells with bone metastasis-initiation capacity that exhibit primary resistance to denosumab in mammosphere assays.
|
28387573 |
2017 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Breast cancers arising in the setting of the hereditary breast cancer genes BRCA1 and BRCA2 are most commonly classified as basal-like breast cancer (BLBC) or luminal breast cancer, respectively.
|
27708239 |
2016 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified two subsets of luminal progenitors (RANK(+) and RANK(-)) in histologically normal tissue of BRCA1-mutation carriers and showed that RANK(+) cells are highly proliferative, have grossly aberrant DNA repair and bear a molecular signature similar to that of basal-like breast cancer.
|
27322743 |
2016 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
|
25048467 |
2014 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CINAHL® and PubMed databases, journals, and citation indices were searched using the key word basal-like in combination with breast cancer, epigenetic, treatment, subtype, risk factor, and BRCA1 to synthesize the literature on the multiple underpinnings of basal-like breast cancer.
|
25355019 |
2014 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1 pathway function in basal-like breast cancer cells.
|
25092866 |
2014 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transient or stable exogenous S100A2 expression inhibits the growth of BRCA1 mutant and basal-like breast cancer cell lines, while short interfering RNA (siRNA) knockdown of S100A2 in non-tumorigenic cells results in enhanced proliferation.
|
24556685 |
2014 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA copy number analysis showed that cases with BRCA1 mutation were significantly associated with amplification both at 8q24 (frequencies: BRCA1 tumors 50%, BRCA2 tumors 32%, and wild-type tumors 9%) and regions of the X-chromosome specifically dysregulated in basal-like breast cancer (BLBC; BRCA1 62%, BRCA2 34%, and wild-type 35%).
|
23633455 |
2013 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our working model is that the high frequency of basal-like breast cancer in BRCA1 mutation carriers is the result of a self-perpetuating triad of cellular phenotypes consisting of: (i) intrinsic defects in DNA repair and centrosome regulation that lead to genomic instability and increases spontaneous transformation; (ii) aberrant lineage commitment; and (iii) increased proliferation due to in large part to increased IGF-1 activity.
|
24131977 |
2013 |
|
Basal-Like Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
|
24004112 |
2013 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that this BRCA1-GATA3 repression complex is not a FOXC1-specific phenomenon as a number of other genes associated with BLBCs such as FOXC2, CXCL1 and p-cadherin were also repressed in a similar manner.
|
22120723 |
2012 |
|
Basal-Like Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
|
22083523 |
2012 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings show the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1 status.
|
22706203 |
2012 |
|
Basal-Like Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was associated with the lymph node metastasis, tumor stage, p53 nuclear accumulation, and BRCA-1 and BRCA-2 expression in BLBC.
|
21625942 |
2011 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is increasing evidence that a triple-negative, basal-like breast cancer (TNBBC) subtype develops mainly through a BRCA1-related pathway.
|
21069385 |
2011 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings establish that transcriptional upregulation of ΔNp63 proteins is critical for BRCA1 suppressor function and that defects in BRCA1-ΔNp63 signaling are key events in the pathogenesis of basal-like breast cancer.
|
21363924 |
2011 |
|
Basal-Like Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 mutations are often associated with basal-like breast cancer, which are also often negative for oestrogen receptor (ER), progesterone receptor (PR) and HER2.
|
20632086 |
2011 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified.
|
19813073 |
2011 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased understanding of the genetic abnormalities involved in the pathogenesis of TNBC, BLBC and BRCA1-associated tumors is opening up new therapeutic possibilities for these hard-to-treat breast cancers.
|
20877296 |
2010 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNBC is a heterogeneous disease that does not offer specific targets in the same way as HR-positive and HER2-positive breast cancers, and is similar to basal-like breast cancer and BRCA1-related breast cancer.
|
20632057 |
2010 |
|
Basal-Like Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data provide an example of a specific and recurrent oncogenic consequence of BRCA1-dependent dysfunction in DNA repair and provide insight into the pathogenesis of BBC with therapeutic implications.
|
18066063 |
2008 |